The future belongs to personalized medicine
The pharmaceutical industry relies on personalized medicine
remedium.ruJune 19, 2009 industry portal bionity.com He reported on the conference on the problems of life sciences of the German Association for Financial Situation Analysis and Asset Management DVFA held in Frankfurt on June 16-17 this year.
It was said at the conference that the pharmaceutical and biotechnological industries pin great hopes on the so-called personalized medicine in the face of increasing competition from generic manufacturers. The discussion on the costs and benefits of certain medicines, as well as savings in healthcare, also requires rethinking. "Giving the right amount of the right medicine to the right patient" is the goal of personalized medicine, as outlined by Julia Schüler, an expert in the field of biotechnology at Ernst & Young audit company.
Personalized medicine is the targeted treatment of a patient based on the results of a study of his "genetic profile". At the same time, first of all, we are talking about using gene analysis to determine whether it is worth taking this or that drug into consideration at all. Because even minor individual differences in the hereditary substance or in the DNA of two patients can lead to the fact that the same drug acts on them in completely different ways. In addition, personalized therapy can reduce costs, says Thomas Schweins, responsible for marketing and strategy at Qiagen. According to Schuyler, the current share of personalized medicine in the amount of $ 700 billion is still quite small for the scale of the global pharmaceutical market. The assessment of the American consulting company "Boston Consulting Group" (BCG) shows that by 2020 the growth rate of personalized medicine will be 37% annually.
Portal "Eternal youth" http://vechnayamolodost.ru/23.06.2009